Subscribe
Core coverageBIIB

Company profile / BIIB

Biogen

Clinaptis stancePositive
ConvictionMedium
Ticker
BIIB
Exchange
NASDAQ
Coverage
Standard profile
Updated
Oct 7, 2026
Neuroscience / Rare Disease / Immunology

Biogen is rebuilding growth around Alzheimer's disease, rare disease, and immunology as its legacy multiple sclerosis franchise contracts. The investment case rests on commercial execution, earnings conversion, and selective pipeline upside.

01 / Clinaptis view

The current read

Positive structural long. The Growth Portfolio has overtaken legacy MS revenue; the next test is whether that crossover delivers sustained growth in revenue and earnings.

  1. Q2 2026 crossover. Growth Portfolio revenue reached $1.06 billion, up 24% year over year, versus $767 million for legacy MS, a roughly $293 million lead. Total revenue rose 3% to $2.74 billion. Skyclarys generated $168 million, up 29%; Leqembi global in-market sales reached $184 million, up 15%, while Biogen recognized $64 million of Alzheimer's collaboration revenue. The Growth Portfolio includes acquired Apellis revenue, and the lead is arithmetic on rounded disclosed figures. Source: Biogen Q2 2026 results.
  2. What has to hold. Subcutaneous Leqembi adoption, Skyclarys expansion, and Apellis execution must sustain that momentum beyond the acquisition contribution. Five registrational readouts across three drugs provide the next clinical tests: two litifilimab SLE studies in Q4 2026, followed by felzartamab in AMR, litifilimab in CLE, and zorevunersen in Dravet syndrome during 2027. Diranersen adds longer-term upside, but its clinical effect remains uncertain. Timing is management's plan, from the Biogen 2Q26 earnings presentation.
  3. What would change our view. Persistent weakness in commercial uptake, faster legacy erosion, or failure to convert Apellis revenue into earnings would weaken the structural long. Negative pivotal data would reduce pipeline upside. Diranersen remains an option whose clinical magnitude and confirmatory trial design are unresolved.
02 / Consensus gap

Where the market may differ

The potential gap is between weaker headline EPS guidance and an improving underlying business, and whether that improvement proves durable.

  1. The EPS bridge. Biogen cut reported 2026 non-GAAP EPS guidance to $12–13, while raising its underlying range by $0.60 to $15.85–16.85. The bridge comprises approximately $3.00 per share of acquired R&D and milestone charges and $0.85 of Apellis dilution. Management expects Apellis to become accretive in 2027, with at least $250 million in annual run-rate synergies exiting that year. Source: Biogen Q2 2026 results.
  2. Our positive view rests on commercial growth translating into earnings as acquisition costs ease. The underlying EPS range excludes real expenses and financing effects; it is a measure of operating momentum, not realized earnings. The market-gap framing is a Clinaptis investment hypothesis, not a claim about current consensus positioning.
  3. The longer-term roadmap. Management's roadmap extends beyond the earnings bridge: seven additional study readouts are planned for 2028–2030, spanning new products and indication expansion for existing assets, in lupus, kidney disease, SMA, Friedreich's ataxia, and earlier Alzheimer's disease. This is a development roadmap, not a launch or revenue forecast, and diranersen's biomarker evidence remains distinct from a confirmed clinical effect.
Coverage state
Standard profile
What the review turns on
Key variable

Growth Portfolio demand and earnings contribution versus legacy MS erosion.

Next catalyst

Litifilimab TOPAZ-1 and TOPAZ-2 Phase 3 SLE readouts, shown in Q4 2026; felzartamab TRANSCEND in AMR and litifilimab AMETHYST in CLE, both expected H1 2027; zorevunersen EMPEROR in Dravet syndrome, shown in Q3 2027. Commercial checkpoints: Leqembi subcutaneous uptake, Skyclarys international demand, and Syfovre / Empaveli performance.

03 / Pipeline

Key programs

11 assets · 11 programs

AssetIndicationStageNext event
Leqembi (lecanemab)
Early Alzheimer's disease; preclinical AD expansion
Commercial; registrational expansion program
Subcutaneous uptake; AHEAD 3-45 readout in the 2028–2030 roadmap
Skyclarys (omaveloxolone)
Friedreich's ataxia
Commercial; pediatric registrational program
International demand; BRAVE pediatric readout in the 2028–2030 roadmap
Syfovre (pegcetacoplan)
Geographic atrophy secondary to AMD
Commercial
Demand, competitive position, and integration execution
Empaveli (pegcetacoplan)
C3G, primary IC-MPGN, and PNH
Commercial
Kidney-disease uptake and commercial execution
Litifilimab
Systemic and cutaneous lupus erythematosus
Phase 3
TOPAZ-1 / TOPAZ-2 in SLE: Q4 2026; AMETHYST in CLE: H1 2027
Felzartamab
AMR, microvascular inflammation in kidney transplant patients, IgA nephropathy, and primary membranous nephropathy
Phase 3 lead kidney programs; additional registrational expansion
TRANSCEND in AMR: H1 2027; TRANSPIRE / PREVAIL / PROMINENT: 2028–2030 roadmap
Diranersen (BIIB080)
Early Alzheimer's disease
Phase 2 completed; Phase 3 planned
Phase 3 dose, population, powering, and duration; extension data
Spinraza (nusinersen)
Spinal muscular atrophy
Commercial; high-dose regimen approved March 2026
High-dose conversion and franchise durability
Salanersen
Spinal muscular atrophy
Phase 1b data reported; STELLAR-1 registrational study in roadmap
STELLAR-1 readout: 2028–2030 window
Zorevunersen
Dravet syndrome
Phase 3
EMPEROR readout shown in Q3 2027
Dapirolizumab pegol
Systemic lupus erythematosus
Registrational program
PHOENYCS FLY readout: 2028–2030 window
04 / Connected research

Published on BIIB

View full archive
  1. 01

    BIIB Alzheimer’s: CELIA Validated Tau, Not the Clinical Effect Size

    The reported 26% slowing likely overstates the underlying effect. That does not mean Biogen chose the wrong dose.

    Read